HUP0400529A3 - Use of chlorpromazine and pentamidine for preparation of pharmaceutical compositions for the treatment of neoplastic disorders - Google Patents

Use of chlorpromazine and pentamidine for preparation of pharmaceutical compositions for the treatment of neoplastic disorders

Info

Publication number
HUP0400529A3
HUP0400529A3 HU0400529A HUP0400529A HUP0400529A3 HU P0400529 A3 HUP0400529 A3 HU P0400529A3 HU 0400529 A HU0400529 A HU 0400529A HU P0400529 A HUP0400529 A HU P0400529A HU P0400529 A3 HUP0400529 A3 HU P0400529A3
Authority
HU
Hungary
Prior art keywords
pentamidine
chlorpromazine
preparation
treatment
pharmaceutical compositions
Prior art date
Application number
HU0400529A
Other languages
English (en)
Original Assignee
Combinatorx Inc Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc Boston filed Critical Combinatorx Inc Boston
Publication of HUP0400529A2 publication Critical patent/HUP0400529A2/hu
Publication of HUP0400529A3 publication Critical patent/HUP0400529A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HU0400529A 2000-11-06 2001-10-30 Use of chlorpromazine and pentamidine for preparation of pharmaceutical compositions for the treatment of neoplastic disorders HUP0400529A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/706,929 US6569853B1 (en) 2000-11-06 2000-11-06 Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
PCT/US2001/047959 WO2002058684A2 (en) 2000-11-06 2001-10-30 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders

Publications (2)

Publication Number Publication Date
HUP0400529A2 HUP0400529A2 (hu) 2004-06-28
HUP0400529A3 true HUP0400529A3 (en) 2006-02-28

Family

ID=24839666

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400529A HUP0400529A3 (en) 2000-11-06 2001-10-30 Use of chlorpromazine and pentamidine for preparation of pharmaceutical compositions for the treatment of neoplastic disorders

Country Status (29)

Country Link
US (4) US6569853B1 (hu)
EP (1) EP1339399B1 (hu)
JP (1) JP2004517915A (hu)
KR (1) KR100720205B1 (hu)
CN (1) CN1484525A (hu)
AR (1) AR035500A1 (hu)
AT (1) ATE318590T1 (hu)
AU (1) AU2002246636B8 (hu)
BG (1) BG107831A (hu)
BR (1) BR0115166A (hu)
CA (1) CA2436799C (hu)
CY (1) CY1105501T1 (hu)
DE (1) DE60117615T2 (hu)
DK (1) DK1339399T3 (hu)
EE (1) EE200300212A (hu)
ES (1) ES2258566T3 (hu)
HR (1) HRP20030460A2 (hu)
HU (1) HUP0400529A3 (hu)
IL (1) IL155795A0 (hu)
IS (1) IS2457B (hu)
MX (1) MXPA03003960A (hu)
NO (1) NO20032036L (hu)
NZ (1) NZ525773A (hu)
PL (1) PL362690A1 (hu)
PT (1) PT1339399E (hu)
RU (1) RU2286769C2 (hu)
SK (1) SK5452003A3 (hu)
TW (1) TWI259077B (hu)
WO (1) WO2002058684A2 (hu)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035935A2 (en) * 1999-11-16 2001-05-25 Oncozyme Pharma Inc. Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer
DE10015818A1 (de) * 2000-03-30 2001-10-18 Infineon Technologies Ag Biosensor und Verfahren zum Ermitteln makromolekularer Biopolymere mit einem Biosensor
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US6992082B2 (en) * 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
CA2451845A1 (en) * 2001-05-31 2002-12-05 The Cleveland Clinic Foundation Ptpase inhibitors and method of using same
FR2825279B1 (fr) * 2001-06-01 2005-04-08 Molecular Engines Lab Medicament utile dans le traitement du cancer
WO2003070158A2 (en) 2001-09-07 2003-08-28 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US20040010045A1 (en) * 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US20050215629A1 (en) * 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
AU2004201240B2 (en) * 2001-09-27 2008-08-07 Bar Ilan University Conjugated Psychotropic Drugs and Uses Thereof
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
AU2003241346A1 (en) * 2002-05-01 2003-11-17 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
AU2003256511A1 (en) * 2002-07-11 2004-02-02 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
WO2004088272A2 (en) * 2003-03-26 2004-10-14 Synergy Biosystems Ltd. Methods to identify biologically active agents and synergistic combinations
CA2534816A1 (en) * 2003-06-12 2004-12-23 Evan Newell Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
KR20070012618A (ko) * 2003-09-18 2007-01-26 콤비네이토릭스, 인코포레이티드 신생물 치료용 약의 조합
TW200526777A (en) * 2003-11-12 2005-08-16 Combinatorx Inc Combinations for the treatment of proliferative diseases
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
WO2005046694A1 (en) * 2003-11-13 2005-05-26 Københavns Universitet Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance
WO2005070126A2 (en) * 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
WO2005094322A2 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
DK1744781T3 (da) 2004-04-30 2012-10-15 Bkg Pharma Aps Behandling af infektionssygdomme
WO2005117847A2 (en) * 2004-06-02 2005-12-15 Combinatorx, Incorporated Methods and compounds for the treatment of neoplasms
CA2595156A1 (en) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Regulation of autophagy and cell survival
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
US20100184710A1 (en) * 2005-04-28 2010-07-22 The Regents Of The University Of Colorado Therapeutic Bifunctional Compounds
WO2006118821A2 (en) * 2005-05-02 2006-11-09 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition
AU2006243337B2 (en) 2005-05-04 2011-09-29 Syncore Biotechnology Co., Ltd Method of administering a cationic liposomal preparation comprising paclitaxel
DE102005024017A1 (de) * 2005-05-25 2006-11-30 Merck Patent Gmbh Chinazolinone
MX2007015511A (es) * 2005-06-07 2008-03-06 Univ Ramot Sales novedosas de farmacos sicotropicos conjugados y procesos para prepararlas.
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US20070202079A1 (en) * 2006-01-11 2007-08-30 Taolin Yi Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
BRPI0709075A2 (pt) 2006-03-20 2011-10-11 Medigene Ag tratamento de cáncer de mama triplo receptor negativo
WO2007149381A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
US20080226596A1 (en) * 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis
US8377990B2 (en) * 2006-07-17 2013-02-19 Ramot At Tel-Aviv University Ltd. Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders
MX2009007235A (es) 2007-01-05 2009-10-16 Bkg Pharma Aps "derivados de tioxanteno utiles para el tratamiento de enfermedades infecciosas.".
EP2124856B1 (en) * 2007-01-09 2018-10-17 Fovea Pharmaceuticals Apparatus for intra-ocular injection
DE102007013855A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
DE102007013854A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydrochinoline
DE102007013856A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydropyrrolochinoline
EP2152276A4 (en) * 2007-05-09 2011-09-14 Traffick Therapeutics Inc SCREENING ASSAY FOR IDENTIFYING CORRECTORS FOR PROTEIN TRANSPORT TROUBLESHOOTING
CN101138558B (zh) * 2007-09-13 2010-08-25 汕头大学医学院 喷他脒及死亡结构域受体配体联合应用
EP2194981B1 (en) * 2007-10-05 2011-11-23 Université de Mons-Hainaut Bisbenzimidazoles as antimalarial agents
WO2009101616A1 (en) * 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
EP2318008A1 (en) * 2008-07-18 2011-05-11 Immune Control, Inc. Binding and inhibiting 5-ht4 receptor
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
AU2010243267A1 (en) * 2009-05-01 2011-11-10 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
US8815844B2 (en) 2009-05-20 2014-08-26 Universite De Geneve Mitochondrial activity inhibitors of cancer-initiating cells and use thereof
US20120277193A1 (en) * 2009-09-21 2012-11-01 President And Fellows Of Harvard College Synergistic Combination Therapy
WO2011070579A1 (en) * 2009-12-09 2011-06-16 Biolinerx Ltd. Methods of improving cognitive functions
US20130165417A1 (en) * 2010-04-23 2013-06-27 University Of Florida Research Foundation Methods and compositions for treating ace2-related disorders
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
PT2550963T (pt) * 2011-07-25 2017-01-19 Dritte Patentportfolio Beteili Ésteres de ácido carboxílico de amidoxima de pentamidina como pró-drogas, e a utilização dos mesmos como fármaco
PT2739285T (pt) * 2011-08-02 2019-03-26 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Inibição seletiva da protease malt1 por meio de derivados de fenotiazina
WO2014086478A1 (en) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
JP6370801B2 (ja) * 2012-12-21 2018-08-08 ベルリクス・ファーマ・インコーポレイテッド 肝疾患または肝障害の治療のための使用および方法
RU2530651C1 (ru) * 2013-11-06 2014-10-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, обладающее противовоспалительным и антифибротическим действием в легочной ткани при цитостатическом воздействии
KR101538264B1 (ko) * 2014-01-24 2015-07-20 계명대학교 산학협력단 티오리다진과 트레일을 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물
CN105153042B (zh) * 2015-07-17 2017-11-24 四川大学 一种化合物及其在制备治疗可卡因成瘾的药物中的用途
WO2020082037A1 (en) * 2018-10-19 2020-04-23 Auransa Inc. Methods for treating a subtype of small cell lung cancer
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
KR102562739B1 (ko) * 2020-09-11 2023-08-03 연세대학교 산학협력단 암의 기원 세포의 사멸용 약학적 조성물
KR102315103B1 (ko) * 2021-01-21 2021-10-20 주식회사 뉴캔서큐어바이오 티오리다진 및 퍼헥실린을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) * 1953-07-14 Phenthiazine derivatives
GB1288376A (hu) 1968-10-29 1972-09-06
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US5104858A (en) 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
CH681780A5 (en) * 1991-02-25 1993-05-28 Patrinove Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s)
US5428051A (en) * 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5602172A (en) * 1994-05-06 1997-02-11 The University Of North Carolina At Chapel Hill Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor
US5521189A (en) * 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5770585A (en) 1995-05-08 1998-06-23 Kaufman; Robert J. Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5723495A (en) * 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US6280768B1 (en) * 1996-07-03 2001-08-28 Prm Pharmaceuticals, Inc. Berberine alkaloids as a treatment for chronic protozoally induced diarrhea
US6008247A (en) * 1998-02-27 1999-12-28 The University Of North Carolina At Chapel Hill 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents
KR20010041811A (ko) 1998-03-12 2001-05-25 온토젠 코포레이션 단백질 티로신 포스파타제의 조절제
WO2000010990A2 (en) * 1998-08-20 2000-03-02 University Of North Carolina At Chapel Hill Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof
US6326395B1 (en) * 1998-09-17 2001-12-04 Duke University Antifungal activity of dicationic molecules
JP3679943B2 (ja) * 1999-03-02 2005-08-03 大日本印刷株式会社 パターン形成体の製造方法
WO2001035935A2 (en) 1999-11-16 2001-05-25 Oncozyme Pharma Inc. Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer
US6777433B2 (en) * 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
AU2001258784A1 (en) * 2000-05-22 2001-12-03 Takeda Chemical Industries Ltd. Tyrosine phosphatase inhibitors
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6642221B1 (en) * 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20030161893A1 (en) * 2001-09-07 2003-08-28 Taolin Yi PTPase inhibitors and methods of using the same
AU2003256511A1 (en) * 2002-07-11 2004-02-02 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
KR20070012618A (ko) * 2003-09-18 2007-01-26 콤비네이토릭스, 인코포레이티드 신생물 치료용 약의 조합
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases

Also Published As

Publication number Publication date
US6569853B1 (en) 2003-05-27
US7148216B2 (en) 2006-12-12
DK1339399T3 (da) 2006-06-19
US20050192274A1 (en) 2005-09-01
HRP20030460A2 (en) 2005-04-30
CA2436799A1 (en) 2002-08-01
AU2002246636B8 (en) 2006-01-19
KR100720205B1 (ko) 2007-05-21
CA2436799C (en) 2007-12-18
CY1105501T1 (el) 2010-04-28
IS2457B (is) 2008-11-15
RU2286769C2 (ru) 2006-11-10
IS6806A (is) 2003-05-05
EP1339399B1 (en) 2006-03-01
ES2258566T3 (es) 2006-09-01
PL362690A1 (en) 2004-11-02
JP2004517915A (ja) 2004-06-17
US20070099906A1 (en) 2007-05-03
NZ525773A (en) 2005-04-29
ATE318590T1 (de) 2006-03-15
US20030166642A1 (en) 2003-09-04
PT1339399E (pt) 2006-07-31
KR20030048460A (ko) 2003-06-19
EP1339399A2 (en) 2003-09-03
IL155795A0 (en) 2003-12-23
NO20032036L (no) 2003-07-04
US6846816B2 (en) 2005-01-25
EE200300212A (et) 2003-08-15
NO20032036D0 (no) 2003-05-06
SK5452003A3 (en) 2004-07-07
MXPA03003960A (es) 2004-09-10
DE60117615T2 (de) 2006-11-09
WO2002058684A2 (en) 2002-08-01
DE60117615D1 (de) 2006-04-27
WO2002058684A3 (en) 2003-04-17
TWI259077B (en) 2006-08-01
BG107831A (bg) 2004-02-27
AR035500A1 (es) 2004-06-02
HUP0400529A2 (hu) 2004-06-28
CN1484525A (zh) 2004-03-24
AU2002246636B2 (en) 2005-12-01
BR0115166A (pt) 2003-12-30

Similar Documents

Publication Publication Date Title
HUP0400529A3 (en) Use of chlorpromazine and pentamidine for preparation of pharmaceutical compositions for the treatment of neoplastic disorders
HUP0300382A3 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
EP1600169A3 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
IL127943A (en) Pharmaceutical and cosmetic compositions for the treatment of skin disorders
HUP0302476A3 (en) Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
HUP0104676A3 (en) Compositions for the treatment of anorectal disorders and their use
HUP0200548A2 (hu) Gyógyszerészeti készítmények és alkalmazásuk
AU2001268710A1 (en) Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
GB0108470D0 (en) Pharmaceutical compositions and their use
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
IL153487A0 (en) Pharmaceutical compositions and methods for use
HUP0204391A3 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
IL153897A0 (en) Pharmaceutical compositions and methods for use
HUP0200439A2 (en) Isonipecotamides for the treatment of integrin-mediated disorders, process for their preparation and pharmaceutical compositions containing them
EP1315499A4 (en) COMPOSITIONS AND METHODS OF TREATING ANORCAL DISEASES
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees